Studies a blood marker of insulin-producing cell health in children with obesity
Looks at a blood marker in children with obesity, with or without diabetes.
Key facts
- Who runs it
- Philippe Klee, MD-PhD
- Where
- Geneva, SwitzerlandSee the site
- Trial code
- Registry title
- Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 22 Nov 2024
- Expected to end
- 31 Dec 2028
- Type of study
- Observational
- Treatments tested
- Measurement of biomarker
- Record updated
- 18 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children aged 12 to 16 with obesity, with or without type 2 diabetes. Blood levels of 1,5-anhydroglucitol are measured to test it as a marker of beta-cell function.
- Age
- 12 to 16 years
- Sex
- Boys and girls
- Disease stage
- Obesity, defined as a body-mass index above the 97th percentile. Type 2 diabetes is not required.
- Earlier treatment
- Must not have taken an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin at the time of joining or in the 2 weeks before. Must not take a drug known to affect liver function.
Main reasons for not taking part
- Diabetes with positive autoantibodies against islets, insulin, islet antigen 2, glutamic acid decarboxylase or Zinc transporter 8
- Known liver disease other than NAFLD
- Treatment with an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin now or in the last 2 weeks
- Treatment with a drug known to affect liver function
- Cannot give informed consent by signature
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Children aged 12 to 16 years
- Obesity. Defined as a body-mass index above the 97th percentile
- Ability to give informed consent as documented by signature
Who cannot take part
- Patients treated with an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin at the time of or less than 2 weeks prior to inclusion
- Patients treated with a drug known to affect liver function
- Patients with diabetes mellitus and positive autoantibodies against islets, insulin, islet antigen 2, glutamic acid decarboxylase or Zinc transporter 8
- Patients with known liver disease (other than NAFLD)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 16 years old?
Where in Switzerland
- University Hospital of GenevaGeneva, SwitzerlandContact: Philippe Klee, MD-PhDTaking people
About the trial
What the trial wants to find out
The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.
The group in the trial
- Children with obesity
Children with obesity followed within the pediatric endocrine and diabetes unit of the University Hospitals of Geneva, Switzerland. The investigators will do prospective measures in 50 children aged 12 to 15 years, at the time of a planned oral glucose tolerance test and again, 2 years later.
Treatment: Measurement of biomarker
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function: From Mice to Children
- Plain-language title
- Studies a blood marker of insulin-producing cell health in children with obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06682481, who can take part
- Record updated
- 18 May 2026